(Q37082491)

18 August 2017

1 reference

title

Angiogenesis as a strategic target for ovarian cancer therapy (English)

1 reference

18 August 2017

1 reference

1 reference

2

Anil K Sood

1 reference

18 August 2017

Whitney A Spannuth

1

1 reference

PubMed ID

18268546

18 August 2017

Robert L Coleman

series ordinal

3

1 reference

18 August 2017

12 February 2008

1 reference

Nature Clinical Practice Oncology

18 August 2017

1 reference

18 August 2017

5

1 reference

18 August 2017

194-204

1 reference

18 August 2017

4

1 reference

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Angiogenic inhibitors: a new therapeutic strategy in oncology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Vasculogenic mimicry and pseudo-comedo formation in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Cellular abnormalities of blood vessels as targets in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Tumor angiogenesis and recurrence in stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Raf: a strategic target for therapeutic development against cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Vascular targeting agents as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Thalidomide in solid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

EphA2 as a target for ovarian cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Predicting benefit from anti-angiogenic agents in malignancy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Circulating endothelial progenitor cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Antitumor and antivascular effects of AVE8062 in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Clinical trial design issues in the era of targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1051

7 January 2021

Identifiers

DOI

10.1038/NCPONC1051

1 reference

18 August 2017

1 reference

PubMed ID

18268546